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Abstract
Plasmodium vivax being the most geographically spread Plasmodium species is 
considered sparsely distributed in sub-Saharan Africa (sSA) while P. falciparum is 
the most prevalent species in this region. Thus, control strategies in sSA have been 
disproportionately targeted towards falciparum malaria. Nevertheless, with the use 
of more sensitive malaria diagnostic platforms, there are more reports of P. vivax 
and other non-falciparum malaria in sSA. In addition, P. vivax is presumed benign, 
however there are new findings of severe cases recorded from P. vivax single or 
mixed infection with other Plasmodium species. Besides, the extended dormant 
period (lasting for weeks or months) is a challenge for achieving effective cure for 
vivax infections. Although, chloroquine has been proscribed for treatment P. falci-
parum, it still remains the drug of choice for P. vivax in most Asian countries where 
it is predominant. In sSA, artemisinin combination-based therapies (ACTs) are used 
for treatment of falciparum malaria and, it is probable that the use of ACT could be 
enhancing adaptive selection for P. vivax in the face of its increasing prevalence in 
the population. Hence, understanding epidemiological and biological factors, and 
data that could be contributing to the observed steady increase in P. vivax preva-
lence in sSA is important. In this chapter, we discuss the mechanisms for invasion 
of red blood cells, trends in increasing prevalence of vivax malaria, diagnostic 
tools, and the public health implications of P. vivax and P. falciparum co-endemicity 
in Africa.
Keywords: Plasmodium vivax, Plasmodium falciparum, sub-Saharan African,  
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1. Introduction
In sub-Saharan Africa (sSA), Plasmodium falciparum is responsible for most of 
the human malaria infection and less frequently, malaria could be due to P. ovale, P. 
malariae and P. vivax [1]. Significant gains observed in massive reduction in global 
malaria cases and mortalities in the early 2000s have been largely due to strategic 
malaria interventions [1]. Nevertheless, signals of reversal in gains are beginning 
to emerge in most African countries [1]. This stall in progress has been attributed 
to increased prevalence of non-falciparum malaria parasites on one hand and the 
development of resistance by both the parasite and vector to drugs and insecticides 
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respectively [2–4]. Thus, refocusing control strategies to include all circulating 
species of Plasmodium in sSA aimed at reducing the burden of these non-falciparum 
parasites will greatly contribute to malaria control progress.
P. vivax is particularly interesting as regards its mechanism of invasion, repro-
duction, virulence and development. Understanding the biology of vivax parasites 
is crucial for developing strategies aimed at controlling malaria. Regrettably, vivax 
malaria poses a huge challenge for in vitro analysis to adapt in cell culture, in order 
to shed more light on invasion patterns, virulence, growth, and reproduction. 
For example, P. vivax has high predisposition for immature red blood cells-RBCs 
(reticulocytes) which is not readily available [5]. Another drawback as regards 
vivax control is the use of primaquine (PQ ) to achieve hypnozoites clearance, 
which causes haemolytic anaemia in glucose 6 phosphate dehydrogenase (G6PD) 
deficient individuals [6, 7]. In sSA with very limited resources for ascertaining the 
G6PD status of individuals, this presents a practical challenge as individuals are 
either treated without their G6PD status known or remain untreated. The implica-
tion of the latter is the prolonged carriage of hypnozoites capable of relapsing weeks 
or months later. It has also been found that individuals with specific cytochrome 
P450 gene polymorphic alleles such as the CYP2D6 do not efficiently metabolise PQ 
and eventually miss out in the clearance of dormant liver parasites [8].
Overcoming vivax resistance to chloroquine [9], which is also a major drawback 
in vivax control is looking promising, with a single dose of tafenoquine seemingly 
independent of CYP2D6-impairement is effective in the prevention of vivax relapse 
[10, 11].
Evolution is shaping the biological interaction between vivax parasites and the 
human host [12, 13]. For instance, there is new evidence counteracting the former 
notion of P. vivax emergence in Asia from vivax-like macaque parasites [14, 15]. Recent 
evolutionary genomic analyses have postulated that vivax most probably originated 
in Africa [16]. Selection for Duffy-negative mutations could have been due to the high 
circulation of P. vivax in ancient Africans [12] which led to the eventual disappearance 
of vivax malaria in most parts of Africa [17]. There is need to carry out a comprehen-
sive characterisation of the Duffy-independent vivax strains in West [18, 19] and East 
Africa [20] in order to understand the genetic similarities and phylogeny between the 
strains and, relationship with emerging zoonotic non-human primate (NHP) malaria.
Although, non-human primates (NHPs) and human vivax species are consid-
ered non-interbreedable (allopatric) [12], it is possible that recombination events 
between vivax parasites of apes and human lineages have occurred to favour the 
adaptation of currently circulating vivax strains [21]. This hypothesis is being 
supported by binding studies of recombinant orthologues; reticulocyte binding 
protein 2- RBP2 and RBP3, to gorillas, humans and chimpanzees erythrocytes’ that 
displayed no evidence of host specificity to invasions of red cells [12]. Moreover, 
there has been detection of ape-like P. vivax in a European returnee from Africa 
[21], while human P. vivax has been identified in monkeys from the wild in South 
America [22]. To infer genetic epidemiology of P. vivax and relationship with 
other closely related species, population genetic studies is necessary. This has been 
employed in P. falciparum to demonstrate the origin, complexity, evolutionary his-
tory, changes in population size and relatedness between parasite populations.
2.  Mechanism of invasion of P. vivax malaria to Duffy antigen receptor 
on red blood cells
Duffy antigen receptor for chemokines (DARC) gene is the fourth erythrocyte 
gene associated with resistance to Plasmodium species [23]. Polymorphisms in other 
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genes associated with malaria are specifically accompanied by severity or protection 
against falciparum malaria. DARC confers protection against vivax malaria [24]. 
DARC has a 36–46 kDa glycoprotein major sub-unit and is made up of 338 amino 
acids (AAs) that is organised into seven transmembrane domain [25] with an extra-
cellular epitope at the N-terminal that mediates P. vivax invasion of RBCs. DARC, 
a non-specific receptor is expressed on erythrocytes and employed by P. vivax 
merozoites in invasion of RBCs [26]. It is located on the long arm of chromosome 1 
(1.q22–1.q23) and possesses two exons [27]. A mutation from a thymine to a cyto-
sine at the GATA-box upstream of the promoter region (33rd position) results in the 
non-expression of DARC on RBCs, giving rise to the FYO* allele also known as the 
Duffy negative phenotype [28].
The FYO* allele is prevalent in sSA as well as in African-Americans but rare in 
other racial groups lacking black admixtures [27]. For instance, all 1000 individuals 
screened in a study in the Gambia were Duffy negative [29]; likewise more than 80% 
of the participants of a study carried out in northern Nigeria were Duffy-negative 
[30]. Similarly, another report among pregnant women in Nigeria confirmed a 9:1 
Duffy negative to positive ratio [31]. Thus, the null expression of the Duffy gene 
and reduced prevalence of P. vivax in sSA suggests an interplay of adaptive features 
being employed by RBC overtime. Consequently, the rare observation of FYA and 
FYB alleles in this part of the world [32, 33] substantiates the argument of the selec-
tive adaptation of the Duffy gene on RBC and its exertion in sSA.
There are several reports of vivax malaria in hitherto low risk regions [34–37] 
in sSA. The first Plasmodium invasion molecules identified was the Duffy binding 
proteins (DBP) otherwise referred to as, erythrocyte-binding-like (EBL) proteins. 
These proteins are characteristically homogenous in their cysteine-rich Duffy-
binding-like (DBL) domains. The EBL protein of P. falciparum and P. knowlesi are 
able to use different receptors in invading the RBC due to variation in EBL gene 
numbers [38]. Therefore, it is likely that, P. vivax having phylogenetic similarity 
to P. knowlesi might have developed diverse EBL proteins also capable of binding 
to other receptors in the RBCs [2]. The high genome diversity in P. vivax [39, 40] 
provides a plausible explanation that supports and augments its capability of 
developing alternative invasion pathways through other receptors [41]. An alternate 
hypothesis is that, P. vivax is more endemic in north Africa as well as the Afro-
Asiatic populations found in Sudan, Somalia [42, 43] and Ethiopia [20, 44] where 
there are higher populations of Duffy positive individuals. In this case, the Duffy 
positive carriers are reservoirs of infection to Duffy negative individuals. Despite 
the two assumptions, the precise route of transmission of P. vivax to/from Africa 
has not been fully established.
3.  Increasing trends of P. vivax in sub-Saharan Africa and potential 
selection for Duffy-negative individuals
Previous reports on vivax epidemiology are now under scrutiny due to the use of 
more sensitive detection tools [37, 45–51]. P. vivax has been detected in south-eastern 
Senegal: a region sharing border with Mali, Guinea Conakry and The Gambia. In 
addition, the detection of Anopheles vector capable of transmitting vivax in Kenya 
[52], as well as identification of vivax in mosquito in a study carried out in Angola 
and Equatorial Guinea [35] points to active transmission of vivax malaria in this sub-
region. In a case report, a pregnant Nigerian residing in Italy visited Nigeria briefly 
and was diagnosed with vivax infection [53], with no further investigation as to the 
source of infection. Whether these infections were transmitted from Duffy positive 
individuals serving as reservoir to the negative individuals was not determined.
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Although DBP1 possess unique sequences and are highly polymorphic [53], as 
revealed from correlation analysis of DBP1 mutations, they do not explain the ability 
of P. vivax to infect Duffy-null Africans [54]. The high haplotype diversity of DBP1 
and its flanking region in Ethiopia is predictive of multiple independent emergence 
of vivax variants that were not purged from the population [55]. Therefore, genome-
wide comparative studies of Duffy-dependent and emerging Duffy-independent 
strains are critical for understanding the different forms of adaptive responses, 
fitness and selection operating in the parasites. The occurrence of DBP1 gene ampli-
fication in Ethiopia [55], Madagascar [56] and Cambodia [57] is implicative of adap-
tation to blood stage infection in the host. A substantial knowledge of the patterns of 
genetic variation in different geographic scales as well as genetic differences between 
populations permits inference of population relatedness or structural variation [58].
4.  Strategies for P. vivax diagnosis in Africa in the era of malaria 
elimination
Diagnosis of P. vivax has relied primarily on two approaches; light microscopy 
and rapid diagnostic tests (non-molecular). However, modern tools (molecular 
based tests) such as PCR tests have been demonstrated to be useful, but has suffered 
widespread utilisation in African countries due to lack of expensive equipment and 
trained personnel to carry these complex assays.
4.1 Light microscopy (LM)
The World Health Organisation’s gold standard for P. vivax testing is the detection 
of parasites in Giemsa stained blood smears by light microscopy [59]. In detecting 
parasitemia from blood, thick smears are more sensitive, while thin smears allow for 
clearer visualisation of the morphology of the parasites for accurate speciation and 
calculation of parasite density. It is recommended that 3 sets of thick and thin smears 
should be collected for analysing P. vivax suspected blood smears. Light microscopy 
has a number of benefits in African health laboratories such as low cost of operation, 
and ease of deployment on the field. However, in Africa, the main constraint in accu-
rate microscopy diagnosis is the lack of trained microscopists, and epileptic power 
supply in most parts of the continent. One of the main challenges in microscopic diag-
nosis of P. vivax is the presence of fewer number of parasites circulating in the blood 
compared to P. falciparum infections making it more likely to report false negatives. 
The preference of P. vivax for reticulocytes which accounts for less than 1% of the 
fraction of erythrocytes in circulation explains the reason for lower parasite densities 
compared to P. falciparum. In addition, clinical immunity to P. vivax infections occur 
earlier and the immune response is effective in the control of parasitemia [60].
4.2 Malaria rapid diagnostic tests (mRDTs)
The use of mRDTs has become very popular and critical to controlling malaria in 
Africa. Malaria RDTs provide results within 15 to 20 minutes, do not require special 
training to interpret results and special storage facilities. The use of mRDTs has con-
tributed significantly to reducing the burden of malaria and is the most commonly used 
approach in rural laboratory settings with a sensitivity as high as 99% for P.  falciparum. 
Malaria RDTs that test for P. vivax detect the P.vivax - pLDH antigen specific to P. vivax, 
or pan-pLDH or aldolase antigens common to all Plasmodium species. The sensitivity of 
mRDTs in detecting P. vivax, is lower [61–63] when compared to those for falciparum 
malaria. Moreover, cross reactions with other disease conditions, presence of certain 
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immunological factors and gametocytaemia can result in false positives. They also 
have a limited shelf life (~24 months) and need to be kept dry and away from extreme 
temperatures (> 40°C). Malaria RDTs are very reliable at high parasitemia, while at 
lower parasitemia chances of false negatives increase [64]. A combination of RDTs with 
light microscopy would significantly improve P. vivax diagnosis in Africa.
4.3 Polymerase chain reaction (PCR)
LM has been the gold standard for malaria diagnosis, but with substantial 
progress in malaria control, interventions have begun to consider asymptomatic 
carriers as well. Hence, there is increase interests in the utilisation of molecular tools 
for detection of sub-microscopic infections. Molecular techniques allow investiga-
tion of 5–10 μL whole blood, which increases test sensitivity when compared to 
0.025–0.0625 μL whole blood) used for LM [59].
PCR based tests such as conventional PCR and real time PCR have been used to 
detect P. vivax mostly in laboratory settings as part of research projects and not usually 
as routine clinical based tests. PCR based tests detect P. vivax with high sensitivities 
in diagnosing asymptomatic people particularly in samples with low parasitemia. 
Molecular based tests have a lower detection limit than both mRDTs and LM. The type 
of input material (DNA, RNA or whole blood) target gene, species detected, primer/
probe composition and concentration, amplification technique (PCR or isothermal), 
read-out (gel electrophoresis, fluorescence detection, lateral flow) and whether it is 
qualitative or quantitative impact on the sensitivity of molecular detection tests. The 
standard molecular marker for Plasmodium species differentiation detection is the 18S 
rRNA genes [65]. In the reference genomes of P. vivax (Sal1 and P01), there are 3 dis-
tinct copies of 18S rRNA that are expressed at different stages [66]. Some of the Pv18S 
rRNA assays in use target only one of the three copies by qPCR [67]. Pv18S rRNA assays 
have also been used to target PV18S rRNA transcripts in addition to the genes [67, 68]. 
The detection of P. vivax in clinical samples can also be improved by targeting high 
multi-copy genes in PCR assays which provides improved sensitivity over low-copy 
Pv18S rRNA approaches. Targeting multicopy genes allows pooling samples in commu-
nity surveys in areas with low parasite prevalence or in elimination settings. Pooling will 
also bring down costs of assays without compromising on the sensitivity. An example of 
a multi-copy gene that has been tested for P. vivax diagnosis is the non-coding subtelo-
meric repeat sequence Pvr 47 which has 14 copies in the P. vivax Sal1 reference genome. 
The Pvr47 single step PCR was almost as sensitive as the P. vivax 18S rRNA nested PCR 
[69]. Other targets such as vir/pir multigene family with high copy numbers similar to 
the var. gene family in P. falciparum have also been tested with limited success [70, 71]. 
Other molecular assays for P. vivax have also targeted the mitochondrial DNA in a 
one-step PCR reaction, loop mediated isothermal amplification or qPCR targeting 
cytochrome C oxidase I (cox1) [72–74], genus-specific PCR followed by targeting vivax 
specific non-coding regions between cytochrome B gene and cox1 [75].
Loop-mediated isothermal amplification (LAMP) assays amplify single or 
multi-copy molecular markers in an isothermal reaction. This technique is useful 
at point of care settings in the field because of ease of implementation and limited 
infrastructure requirement. LAMP is also useful in detecting submicroscopic 
 infections with high sensitivity [76, 77].
5. Public health implications of P. vivax and P. falciparum co-endemicity
Co-infections of P. vivax and P. falciparum are often unrecognised in sSA, likely 
due to the predominance of P. falciparum as the major infecting species in most 
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parts of the continent and the dogma that P. vivax was absent in sSA [78, 79]. With 
several lines of evidence, it is now being appreciated that P. vivax prevalence in sSA 
might actually be much higher than presumed [80–82]. Detection of mixed spe-
cies infection with Plasmodium vivax, are also missed as most health care facilities 
use mRDTs specific for P. falciparum and usually do not have skilled man-power 
and resources to analyse all species that might be present by microscopy. In health 
facilities that use microscopy, misdiagnosis of co-infections of P. falciparum and P. 
vivax as P. vivax mono-infection, will lead to wrong treatment which could increase 
antimalarial resistance or P. falciparum parasitemia, leading to severe malaria. There 
are conflicting reports on the impact of co-infections of P. falciparum and P. vivax, 
some studies reported a decrease in disease severity through cross species immunity 
[83], while others have suggested an increased morbidity in children [84]. A recent 
meta-analysis also demonstrated a high prevalence of severe mixed malaria com-
pared to P. falciparum mono-infection in the studies included in the meta-analysis 
[85]. This finding has serious implications on malaria public health control efforts 
and further reiterates the reason why malaria remains a leading cause of morbidity 
and mortality globally. Also, this emphasises the importance of improved diagnos-
tic tools and the use of species-specific mRDTs in combination with routine micros-
copy or PCR where present for continuous surveillance. The possibility of mixed 
infections resulting in a significantly higher risk of developing severe malaria than 
patients with P. falciparum mono-infections is a grave public health risk, consider-
ing that mixed infections are underreported in sSA [86, 87]. This could be one of 
the reasons why treatment failure from ACT use and antimalarial drug resistance 
is on gradual increase on the continent. Taken together, it is important that clinical 
laboratories recognise the likelihood of other non-falciparum species especially 
vivax in their setting, considering the movement of persons (due to trade within 
the continent) that could carry parasites from one location to the other. Therefore, 
improved capacity for detection of suspected cases of mixed infections through 
a combination of species specific mRDTs together with microscopy is crucial for 
accurate treatment.
6. Conclusion
Duffy negativity is no longer a guaranteed barrier against P. vivax invasion, 
and the transmission of Duffy-independent adapted-vivax parasites will interrupt 
malaria control. National malaria elimination programmes should prioritise P vivax 
surveillance. Focus should also be on P. vivax biology especially as it concerns eryth-
rocyte invasion in order to improve control strategies. Fine-scale epidemiological 
mapping is also required to elucidate the evolutionary dynamics of erythrocyte 
invasion by P. vivax.
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